Stock Performance: Shares of PepGen Inc. surged over 115% to $5.74 in after-hours trading following positive results from the 15 mg/kg dose cohort of its FREEDOM-DM1 trial for myotonic dystrophy type 1 (DM1).
Trial Results: The FREEDOM-DM1 trial showed a mean splicing correction of 53.7% in patients receiving the highest dose, indicating potential for reversing molecular defects associated with DM1, with no serious adverse events reported.
PEPG
$5.51+Infinity%1D
Analyst Views on PEPG
Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 5.470
Low
3.00
Averages
10.00
High
20.00
Current: 5.470
Low
3.00
Averages
10.00
High
20.00
H.C. Wainwright
Andrew Fein
Buy
maintain
$18 -> $20
2025-11-13
Reason
H.C. Wainwright
Andrew Fein
Price Target
$18 -> $20
2025-11-13
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on PepGen to $20 from $18 and keeps a Buy rating on the shares. A new U.S. composition of matter patent for PGN-EDODM1 securing exclusivity into the 2040s reinforces the durability of its myotonic dystrophy type 1 franchise, the analyst tells investors.
H.C. Wainwright
Andrew Fein
Buy
maintain
$12 -> $18
2025-10-28
Reason
H.C. Wainwright
Andrew Fein
Price Target
$12 -> $18
2025-10-28
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on PepGen (PEPG) to $18 from $12 and keeps a Buy rating on the shares. The firm believes Novartis' (NVS) acquisition of Avidity (RNA) "has reshaped sentiment across the neuromuscular oligonucleotide space." PepGen's recent rally still leaves the stock at a "steep discount" to peers despite delivering "best-in-class" myotonic dystrophy type 1 data, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$8 -> $12
2025-09-25
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $12
2025-09-25
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on PepGen to $12 from $8 and keeps a Buy rating on the shares. The company reported 53.7% mean splicing correction at 15 mg/kg in the FREEDOM single dose study, the highest level disclosed in myotonic dystrophy type 1 patients to date, the analyst tells investors in a research note. The firm says one patient experienced a transient, reversible renal biomarker elevation that although resolved without intervention, indicates that the program "might not be out of the woods yet." However, PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.
Guggenheim
Debjit Chattopadhyay
initiated
$6
2025-09-09
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
$6
2025-09-09
initiated
Reason
Guggenheim analyst Debjit Chattopadhyay initiated coverage of PepGen with a Buy rating and $6 price target.
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
